1Overview of biopharmaceuticals regulatory science development in ChinaWANG Jun-zhi2465-24712Nonclinical safety study of vaccinesLIU Li, LI Bo2472-24813General technical requirements for production and quality control of human gene therapy productsLI Yong-hong, BI Hua, SHI Xin-chang, QIN Xi, RAO Chun-ming2482-24894Establishment of reference materials for in vitro diagnostics of lung cancer relevant mutations based on next-generation sequencingLIU Dong-lai, ZHANG Xin-yuan, ZHOU Hai-wei, SHEN Shu, WANG Hai-bo, ZHANG Chun-tao2490-24975Development of a novel process for purification of acellular component pertussis vaccineHU Ye-qin, DUAN Kai, LI Xin-guo, PAN Cong, TIAN Cong, TANG Rong-xing, ZHU De-wu, QU Ming-xia, YANG Xiao-ming2498-25046Challenges and suggestions on the implementation of Marketing Authorization Holder for blood products in ChinaDAI Wei, WANG Xue-wei, YANG Lu-yao, SHI Nan, YANG Yue2505-25107Quality evaluation for biological effectiveness of human mesenchymal stem cellsHAN Xiao-yan, NA Tao, ZHANG Ke-hua, YUAN Bao-zhu2511-25188Method validation of CHO host cell residual DNA quantitative kit (PCR-Taqman probe)L(U) Ping, YANG Zhi-xing, ZHANG Hui, ZONG Wei-ying, WU Wan-xin, WANG Tao, LIANG Cheng-gang2519-25269Progress in clinical research of prophylactic human papillomavirus vaccineYU Bang-wei, LI Ke, ZHOU Chen-liang, CHEN Zhu2527-253310Advance in pharmacokinetic studies of antisense oligonucleotidesFU Jie, WANG Hai-xue, SONG Hai-feng2534-254311Progress in research of casein as a nanocarrier for drug deliveryHAN Dan, LIU Chen-guang2544-254912Comparison the main point of guidelines on biosimilars between China and abroadMEI He-kun, WANG Jin, CHAI Dong, WANG Rui, LIANG Bei-bei, BAI Nan, CAI Yun2550-255613Advances in monoclonal antibodies for the treatment of gastric cancerLI Ya-jing, LIU Hong-tao, WU Hui-zhen, WANG Lin-shan, XING Xiao-qing, DONG Zhan-jun2557-256314The MD simulation of the effect of chlorobutanol on the distribution of oxytocin in solutionXU Yi-qi, WU Yan-lin, MENG Fan-cui, REN Yu, TAN De-jiang, MEI Mei2564-257115General issues in clinical trials of recombinant human coagulation factor Ⅷ and ⅨJI Shuang-min, XIONG Wen-xiang, YU Ai-ping, RAO Ya-lan, YANG Huan, GAO Chen-yan2572-257716Research progress and safety characteristics of recombinant human insulin analoguesYIN Hua-jing, YU Shan-shan, YIN Mao-shan, WANG Yin, WU Shuang, LI Zheng, HU Xiao-min2578-258317Analysis for the registration process of biological products in ChinaLIU Zhi-lei, ZHANG Yan-yan, LI Xiao-fang2584-258718FDA recommendation for in vitro bioequivalence studies of phosphate binding agentsSHI Jing2588-2592 